CompletedNot Applicable

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

Taiwan8 participantsStarted 2023-08-01

Plain-language summary

The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune checkpoint blockade (ICB) and asparaginase.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients who have previously received immune checkpoint blockade therapy but are still experiencing disease progression - Exclusion Criteria: Active autoimmune disease \-

What they're measuring

Quantitative Analysis of Plasma EBV DNA Levels for Treatment Response

Timeframe: Until the end of the study

Trial details

NCT IDNCT06676293

SponsorChang Gung Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-30

View on ClinicalTrials.gov More Nasopharyngeal Carcinoma (NPC) trials